Objective:

2

To assess efficacy of Chinese medicine (CM) on insomnia considering characteristics of treatment based on syndrome differentiation.

Methods:

2

A total of 116 participants aged 18 to 65 years with moderate and severe primary insomnia were randomized to the placebo (

n

=20) or the CM group (

n

=96) for a 4-week treatment and a 4-week follow-up. Three CM clinicians independently prescribed treatments for each patient based on syndromes differentiation. The primary outcome was change in total sleep time (TST) from baseline. Secondary endpoints included sleep onset latency (SOL)

wake time after sleep onset (WASO)

sleep efficiency

Pittsburgh Sleep Quality Index (PSQI) and CM symptoms.

Results:

2

The CM group had an average 0.6 h more (95% confidence interval (CI): 0.3–0.9

P

<

0.001) TST and 34.1% (10.3%–58.0%

P

=0.005) more patients beyond 0.5 h TST increment than that of the placebo gr

oup. PSQI was changed –3.3 (–3.8 to –2.7) in the CM group

a –2.0 (–3.2 to –0.8

P

<

0.001) difference from the placebo group. The CM symptom score in the CM group decreased –2.0 (–3.3 to –0.7

P

=0.003) more than the placebo group. SOL and WASO changes were not significantly different between groups. The analysis of prescriptions by these clinicians revealed blood deficiency and Liver stagnation as the most common syndromes. Prescriptions for these clinicians displayed relative stability

while the herbs varied. All adverse events were mild and were not related to study treatment.

Conclusions:

2

CM treatment based on syndrome differentiation can increase TST and improve sleep quality of primary insomnia. It is effective and safe for primary insomnia. In future studies

the long-term efficacy validation and the exploratory of eutherapeutic clinicians' fixed herb formulas should be addressed. (Registration No. NCT01613183)